Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Biotricity (BTCY) reported Q2 FY25 financial results with 13% year-over-year revenue growth to $3.3 million. The company achieved significant improvements in key metrics, including gross margins increasing to 75.3% from 69.1% year-over-year. Recurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentage. The company reduced SG&A by 35.5% to $2.25 million and decreased net loss by 57.4% to $1.65 million. Notably, Biotricity achieved positive cash flow in September on a current operating basis, before interest, dividends, and amortization, with management expecting continued improvement in cash flows.
Biotricity (BTCY) ha riportato i risultati finanziari del secondo trimestre dell'anno fiscale 25, evidenziando una Crescita dei ricavi del 13% rispetto all'anno precedente, arrivando a 3,3 milioni di dollari. L'azienda ha ottenuto significativi miglioramenti in metriche chiave, inclusi i margini lordi che sono aumentati al 75,3% rispetto al 69,1% dell'anno scorso. I ricavi da Commissioni Tecnologiche Ricorrenti hanno costituito il 94% del fatturato totale con una percentuale di profitto lordo del 79%. La società ha ridotto le spese di vendita, generali e amministrative del 35,5%, scendendo a 2,25 milioni di dollari e diminuendo la perdita netta del 57,4%, fissandosi a 1,65 milioni di dollari. È notevole che Biotricity ha raggiunto un flusso di cassa positivo a settembre su base operativa attuale, prima degli interessi, dividendi e ammortamenti, con la direzione che si aspetta un miglioramento continuo nei flussi di cassa.
Biotricity (BTCY) informó resultados financieros del segundo trimestre del año fiscal 25, destacando un crecimiento de ingresos del 13% en comparación con el año anterior, alcanzando 3.3 millones de dólares. La compañía logró mejoras significativas en métricas clave, incluidos márgenes brutos que aumentaron al 75.3% desde el 69.1% del año anterior. Los ingresos por Cuota Tecnológica Recurrente representaron el 94% del ingreso total con un porcentaje de beneficio bruto del 79%. La empresa redujo sus gastos de ventas, generales y administrativos en un 35.5%, hasta 2.25 millones de dólares, y disminuyó la pérdida neta en un 57.4%, a 1.65 millones de dólares. Es notable que Biotricity logró un flujo de efectivo positivo en septiembre sobre una base operativa actual, antes de intereses, dividendos y amortización, con la dirección esperando una mejora continua en los flujos de efectivo.
Biotricity (BTCY)는 회계연도 25년 2분기 재무 결과를 보고하였으며, 전년 대비 13%의 매출 증가를 기록하여 330만 달러에 도달했습니다. 회사는 주요 지표에서 상당한 개선을 이뤘으며, 총 이익률이 지난해의 69.1%에서 75.3%로 증가했습니다. 반복 기술 수수료 수익은 전체 수익의 94%를 차지하며, 총 이익률은 79%에 달했습니다. 회사는 판매, 일반 및 관리비(SG&A)를 35.5% 줄여 225만 달러로 낮췄고, 순손실을 57.4% 줄여 165만 달러로 감소시켰습니다. 특히 Biotricity는 9월에 이자, 배당금 및 감가상각 이전의 현재 운영 기준으로 긍정적인 현금 흐름을 달성했으며, 경영진은 현금 흐름이 계속 개선될 것으로 예상하고 있습니다.
Biotricity (BTCY) a annoncé les résultats financiers du deuxième trimestre de l'exercice 25, avec une croissance des revenus de 13% par rapport à l'année précédente, atteignant 3,3 millions de dollars. L'entreprise a réalisé des améliorations significatives dans des indicateurs clés, notamment une marge brute augmentant à 75,3% contre 69,1% l'an dernier. Les revenus provenant des frais technologiques récurrents ont constitué 94% du chiffre d'affaires total avec un pourcentage de bénéfice brut de 79%. L'entreprise a réduit ses frais de vente, généraux et administratifs de 35,5% à 2,25 millions de dollars et a diminué sa perte nette de 57,4% à 1,65 million de dollars. Il est notable que Biotricity a atteint un flux de trésorerie positif en septembre sur une base opérationnelle actuelle, avant intérêts, dividendes et amortissements, avec une direction s'attendant à une amélioration continue des flux de trésorerie.
Biotricity (BTCY) berichtete über die finanziellen Ergebnisse des 2. Quartals des Geschäftsjahres 25 und verzeichnete ein Umsatzwachstum von 13% im Jahresvergleich, was 3,3 Millionen Dollar entspricht. Das Unternehmen erreichte bedeutende Verbesserungen in wichtigen Kennzahlen, einschließlich der Bruttomarge, die von 69,1% im Vorjahr auf 75,3% anstieg. Die wiederkehrenden Technologiegebühr-Einnahmen machten 94% des Gesamtertrags aus, mit einem Bruttogewinn von 79%. Das Unternehmen reduzierte SG&A um 35,5% auf 2,25 Millionen Dollar und verringerte den Nettoverlust um 57,4% auf 1,65 Millionen Dollar. Bemerkenswert ist, dass Biotricity im September einen positiven Cashflow auf einer aktuellen Betriebsbasis vor Zinsen, Dividenden und Abschreibungen erzielte, wobei das Management mit einer weiteren Verbesserung des Cashflows rechnet.
- Revenue increased 13% YOY to $3.3 million
- Gross margins improved to 75.3% from 69.1% YOY
- Net loss decreased 57.4% to $1.65 million
- SG&A expenses reduced by 35.5% to $2.25 million
- Achieved positive operating cash flow before interest, dividends, and amortization
- Recurring Technology Fee revenue comprises 94% of total revenue
- Company still operating at a net loss of $1.65 million
- Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improve
- Company reports Q2-FY25 revenue grew by
13% YOY to$3.3 million - Gross margins continued to meet management expectations for improvement at
75.3% , a significant improvement from69.1% for the same period last year - Recurring Technology Fee revenue comprised
94% of total revenue with a79% gross profit percentage - Recurring technology fees, additional device sales to existing customers see continued growth
- Reduced SG&A to
$2.25 million from$3.5 million , down35.5% compared to the same period last year - Net loss attributable to common decreased
57.4% to$1.65 million - Management continues to drive revenues and efficiencies; at the end of Q2-FY25
- Management will host its Q2 Fiscal Year 2025 Financial Results Call on Friday, November 15th at 4:30 p.m. ET
REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2025 year and (unaudited) ended September 30, 2024.
Dr. Waqaas Al-Siddiq, Biotricity’s Founder & CEO, said, "In the second quarter of fiscal 2025, we continued our mission to produce transformative healthcare technologies, while demonstrating our strong commitment to automation, operational efficiency and financial discipline. Our primary focus remains on driving revenue and margins, and we were pleased to see these metrics trend upwards. This quarter, we continued to leverage our data intelligently, optimizing patient outcomes through continuous development and advancement of our innovative diagnostic solutions.
Our Biocore suite of products, combined with our robust platform, continues to improve in response to feedback received from cardiologists and electrophysiologists who seek to provide superior patient care. We have now recorded hundreds of billions of heartbeats as part of our Cardiac AI cloud. Over the past two years, our solutions have made a significant impact, with more than 50K atrial fibrillation (Afib) diagnoses, a leading cause of stroke . Our technology offers patients the prospect of earlier medical intervention, producing substantial healthcare savings for both patients and the healthcare system.
Building on this success, Biotricity has expanded our AI technology development in remote cardiac care, harnessing proprietary AI technology to develop a suite of predictive remote monitoring tools that enhance new disease profiling, improve patient management, and revolutionize disease prevention. The results for our second quarter demonstrate year-over-year revenue growth and improvements in all key operating metrics- specifically in recurring technology fees, device sales, and gross margins. Throughout this, we've maintained a strong focus on cost control and expense management, and we continue to make consistent progress towards our goal of achieving positive cash flow and profitability."
Q2-FY25 Financial Highlights
- Revenue increased by
13% YOY to$3.3 million in Q2 FY25 - Gross profit percentage was
75.3% for the three months ended September 30, 2024, as compared to69% in the corresponding prior year quarter. This increase in gross margin was primarily attributed to improved margins on technology fees and gained efficiencies in using AI in data processing. Going forward the Company anticipates continued strong performance in overall blended gross margins. - Net loss decreased
57% YOY to$1.65 million , or$0.07 3 per share, from a net loss$3.88 million , or$0.44 6 per share, in Q2-FY24
Operating Highlights for Q2-FY25
- Q2-FY25 recurring (TaaS) Technology Fees rose a
12.2% YOY to$3.06 million ;73% of this revenue was flat fee revenue, which grew by34% from the prior year period, which is a growing percentage of the Company’s business - Posted efficiency gains evident in YOY reductions of
9.5% in Cost of Revenue and34% in Total Operating Expenses for Q2-FY25; Company is driven to reach positive cash flow, driving revenue higher while reducing or holding SG&A stable Achieved positive cash flow on current operating basis, before interest, dividends and amortization achieved at the end of the quarter; next quarter expected to continue to see cash flows improve - Company maintained its strong customer retention track record, supported by quality of customer and cardiologist-friendly support services that emphasize accuracy of diagnostics and ease-of-use.
- Continued to expand its customer base with an increased focus on hospital networks; currently being used by over hundreds of centers across 35 states with thousands of cardiologists
Full details of the Company’s financial results will be filed with the SEC on Form 10-Q and available by visiting www.sec.gov.
Financial Results and Business Update Conference Call
Management will host a conference call on Friday, November 15, 2024 at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://www.biotricity.com/investors/
Event: Biotricity Second Quarter FY 2025 Financial Results and Business Update Call
Date: Friday, November 15, 2024
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1697705&tp_key=6ae5e1a902
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.
Toll Free Replay Number: 844-512-2921
International: 1-412-317-6671
Replay Access ID: 13750135
Expiration: November 29, 2024 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
investors@biotricity.com
FAQ
What was Biotricity's (BTCY) revenue growth in Q2 FY25?
What were BTCY's gross margins in Q2 FY25?
How much did Biotricity (BTCY) reduce its net loss in Q2 FY25?
What percentage of BTCY's Q2 FY25 revenue came from recurring Technology Fees?
